These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25111500)

  • 21. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.
    Ogisu K; Kudo K; Sasaki M; Sakushima K; Yabe I; Sasaki H; Terae S; Nakanishi M; Shirato H
    Neuroradiology; 2013 Jun; 55(6):719-24. PubMed ID: 23525598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visualization of neuromelanin in the Substantia nigra and locus ceruleus at 1.5T using a 3D-gradient echo sequence with magnetization transfer contrast.
    Nakane T; Nihashi T; Kawai H; Naganawa S
    Magn Reson Med Sci; 2008; 7(4):205-10. PubMed ID: 19110515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative T1, T2, and T2* Mapping and Semi-Quantitative Neuromelanin-Sensitive Magnetic Resonance Imaging of the Human Midbrain.
    Hashido T; Saito S
    PLoS One; 2016; 11(10):e0165160. PubMed ID: 27768782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.
    Wang J; Huang Z; Li Y; Ye F; Wang C; Zhang Y; Cheng X; Fei G; Liu K; Zeng M; Zhong C; Jin L
    Parkinsonism Relat Disord; 2019 Jan; 58():3-8. PubMed ID: 30037690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease.
    Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S
    Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
    Kashihara K; Shinya T; Higaki F
    Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.
    Kuya K; Shinohara Y; Miyoshi F; Fujii S; Tanabe Y; Ogawa T
    Neuroradiology; 2016 Apr; 58(4):351-6. PubMed ID: 26779912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuromelanin-related contrast in the substantia nigra semiquantitatively evaluated by magnetic resonance imaging at 3T: comparison between normal aging and Parkinson disease].
    Tanaka M; Aihara Y; Ikeda S; Aihara Y
    Rinsho Shinkeigaku; 2011 Jan; 51(1):14-20. PubMed ID: 21387694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions.
    Elstner M; Müller SK; Leidolt L; Laub C; Krieg L; Schlaudraff F; Liss B; Morris C; Turnbull DM; Masliah E; Prokisch H; Klopstock T; Bender A
    Mol Brain; 2011 Dec; 4():43. PubMed ID: 22188897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy.
    Matsuura K; Maeda M; Yata K; Ichiba Y; Yamaguchi T; Kanamaru K; Tomimoto H
    Eur Neurol; 2013; 70(1-2):70-7. PubMed ID: 23796701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardized Data Acquisition for Neuromelanin-sensitive Magnetic Resonance Imaging of the Substantia Nigra.
    Salzman G; Kim J; Horga G; Wengler K
    J Vis Exp; 2021 Sep; (175):. PubMed ID: 34570093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
    Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
    Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic Resonance Imaging Biomarkers to Assess Substantia Nigra Damage in Idiopathic Rapid Eye Movement Sleep Behavior Disorder.
    Pyatigorskaya N; Gaurav R; Arnaldi D; Leu-Semenescu S; Yahia-Cherif L; Valabregue R; Vidailhet M; Arnulf I; Lehéricy S
    Sleep; 2017 Nov; 40(11):. PubMed ID: 28958075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla.
    Shibata E; Sasaki M; Tohyama K; Kanbara Y; Otsuka K; Ehara S; Sakai A
    Magn Reson Med Sci; 2006 Dec; 5(4):197-200. PubMed ID: 17332710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromelanin imaging analyses of the substantia nigra in patients with Machado-Joseph disease.
    Nakata Y; Sakamoto A; Kawata A
    Neuroradiology; 2020 Nov; 62(11):1433-1439. PubMed ID: 32556403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced signal of locus ceruleus in depression in quantitative neuromelanin magnetic resonance imaging.
    Shibata E; Sasaki M; Tohyama K; Otsuka K; Sakai A
    Neuroreport; 2007 Mar; 18(5):415-8. PubMed ID: 17496795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.
    Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M
    Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.